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The immaturity of neurons differentiated from human induced pluripotent stem cells (hiPSCs) presents diffi-
culties for modeling late-onset neurodegenerative disorders such as Parkinson’s disease. Now, Miller et al.
(2013) provide a strategy for inducing aging-related phenotypes in hiPSC-derived neurons, enabling in vitro
study of late-onset neurodegenerative diseases.The discovery that somatic cells can be
reprogrammed to human induced plurip-
otent stem cells (hiPSCs), acquiring the
potential to differentiate to any cell type
in the human body, has made it possible
to develop patient-specific cell-based
models for the study of complex diseases
in vitro. Modeling adult-onset disorders
presents unique challenges, because
hiPSC-derived cells generally resemble
fetal, rather than adult, tissue. For
instance, gene expression profiling of
hiPSC-derived neurons has shown that
these cells typically differentiate at a rate
comparable to that of their fetal counter-
parts (Mariani et al., 2012; Nicholas
et al., 2013). This delayed maturation
appears to mirror in vivo developmental
timing, as even with months of prolonged
culture, hiPSC-derived neurons fail to
resemble adult temporal identity. Thus, it
may be more accurate to state that cur-
rent hiPSC-based studies have modeled
genetic predisposition to disease, rather
than the disease state itself. Recent
hiPSC-based studies of late onset neuro-
degenerative diseases have failed to
recapitulate the severe neuronal loss
observed in human disease. Instead,
hiPSC neurons derived from patients
with Parkinson’s disease (PD) (Byers
et al., 2011; Chung et al., 2013; Liu et al.,
2012; Nguyen et al., 2011), Alzheimer’s
disease (AD) (Israel et al., 2012; Kondo
et al., 2013), and Amyotrophic lateral
sclerosis (ALS) (Sareen et al., 2013)
show evidence of early biochemical phe-
notypes and increased susceptibility to
cellular stress rather than overt manifesta-
tions of degeneration. In this issue of Cell
Stem Cell, Miller et al. (2013) describe a
method to overcome these limitations
and successfully model age-dependentneurodegeneration using hiPSC-derived
neurons.
Miller and colleagues first investigated
whether the molecular phenotypes of ag-
ing are maintained during hiPSC reprog-
ramming. Fibroblasts from old donors
were characterized by abnormal nuclear
morphology, loss of nuclear lamina-asso-
ciated proteins and peripheral hetero-
chromatin markers, and increased DNA
damage and mitochondrial superoxide
levels relative to fibroblasts from younger
donors. These fibroblasts were then re-
programmed to hiPSCs and subsequently
differentiated back into fibroblasts. In
contrast to their previous results, Miller
et al. found that, with respect to aging
markers, redifferentiated fibroblasts from
aged-donor hiPSCs were indistinguish-
able from those redifferentiated from
young donor-derived hiPSCs.
Next, the authors compared fibroblasts
obtained from patients with Hutchinson-
Gilford progeria syndrome (HGPS) to
those from healthy young and old donors.
HGPS is a rare genetic disorder charac-
terized by premature aging; it is caused
by amutation in the nuclear envelope pro-
tein gene lamin A (LMNA) that results in
a shorter transcript known as progerin.
Progerin protein inhibits the function of
normal LMNA as a scaffolding protein,
affecting chromatin organization, DNA
damage response, cell cycle, and telo-
mere function, ultimately leading to pre-
mature aging and cellular senescence.
The authors found that fibroblasts
from (young) HGPS donors displayed
similar aging characteristics as those
from old donors. When the authors
reprogrammed HGPS-derived fibroblasts
into hiPSCs and redifferentiated fibro-
blasts, they found that these were theCell Stem Cell 13,only hiPSC-derived fibroblasts that pre-
maturely re-expressed aging markers.
Based on this observation, Miller
and colleagues asked whether transient
expression of progerin could induce
aging-related phenotypes in vitro (Fig-
ure 1). Indeed, both young and old
hiPSC-derived fibroblasts expressed ag-
ing-related markers after just 3 days of
progerin overexpression. Progerin-ex-
pressing hiPSC fibroblasts, regardless of
donor age, displayed nuclear morphology
abnormalities, DNA damage, loss of het-
erochromatin markers, and increased
mitochondrial dysfunction, together with
decreased telomere length and increased
senescence. Miller et al. then tested
whether the same effects were observed
in hiPSC-derived midbrain dopaminergic
(mDA) neurons. In these mDA neurons,
progerin overexpression resulted in not
just increased DNA damage and mito-
chondrial dysfunction, but also age-
related mDA neuronal phenotypes such
as reduced dendrite length and increased
neuromelanin production.
The authors then tested whether
expression of progerin in mDA neurons
could enhance the emergence of pheno-
types associated with neurodegenera-
tive diseases such as PD, which have
not been faithfully recapitulated in cur-
rent hiPSC-based models. mDA neurons
were differentiated from hiPSCs derived
from patients with mutations in either
of two highly penetrant PD genes: PINK1
or Parkin. Overexpression of progerin
in these PD hiPSC mDA neurons re-
sulted in significant and specific dis-
ease-related phenotypes that mimicked
late-onset PD, including dendrite degen-
eration, apoptosis, mitochondrial defects,





















Figure 1. Progerin-Induced Cellular Aging
Ectopic expression of just one factor, progerin, is sufficient to restore cellular and molecular markers of
aging in patient fibroblasts following redifferentiation from induced pluripotent stem cells. In addition, pro-
gerin expression partially infers an ‘‘old’’ identity to hiPSC-derived neurons, transforming them into an
ideal platform for the in vitro study of age-related neurodegenerative disorders.
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tion. The authors then grafted mDA
neurons from control or PD-hiPSCs
into a mouse model of PD. Whereas
control mDA neurons, with or without
progerin overexpression, were able to
improve disease-related behavioral phe-
notypes, transplantation of PD-iPSC-
derived mDA neurons overexpressing
progerin were not able to do so. This
was associated with PD- and progerin-
specific effects on neuron survival and
ultrastructure. These results demonstrate
that progerin-induced aging enabled the
emergence of complex disease-related
phenotypes, significantly improving hiPSC-
based models of neurodegenerative
disease.
What remains unclear is the relevance
of progerin-induced aging for hiPSC-
based studies of adult onset psychiatric
disorders such as schizophrenia, bipolar
disorder, and addiction. These disorders
are more closely linked to deficits in
neurotransmitter output of complicated
neuronal networks than they are to
aging, and they may reflect interplay be-
tween several additional mechanisms of
neuronal maturation including activity-
dependent modulation of neuronal cir-636 Cell Stem Cell 13, December 5, 2013 ª2cuits, microglia-mediated synaptic prun-
ing, and oligodendrocyte myelination.
These multifactorial interactions may
be more difficult to model using the
approach described by Miller et al. As
the authors themselves caution, pro-
gerin-induced changes likely represent a
degenerative response and so do not
capture all aspects of normal aging. While
continued pursuit of alternative aging pro-
tocols for hiPSC-derived neurons remains
necessary to facilitate the investigation of
other neurological disorders, this work
will prove immediately transformative for
studies of PD, AD, and ALS.
hiPSC-based studies of age-depen-
dent neurodegeneration can now investi-
gate features that manifest late in dis-
ease progression, rather than those that
just reflect disease predisposition. This
makes possible the immediate develop-
ment of high-throughput screening plat-
forms to identify novel therapeutic inter-
ventions that might prove clinically
relevant after the onset of symptoms in
patients. However, this work ultimately
represents much more than a break-
through in cell-based models of neurode-
generation. Beyond this demonstrated
utility in neurons, progerin-induced aging013 Elsevier Inc.may prove useful in accelerating the
maturation of many other hiPSC-derived
cells, improving models for diseases
ranging from cardiac failure to cirrhosis
to diabetes. This will enable scientists to
model the molecular and cellular factors
contributing to a range of age-related dis-
eases and to ultimately seek means to
prevent or reverse these processes.
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